Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~31 mi. (Offenbach, Germany, +207 more cities)

Sana Klinikum Offenbach GmbH ( Site 1002)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

~31 mi. (Offenbach, Germany, +94 more cities)

Sana Klinikum Offenbach

HER2 Negative

Breast Carcinoma

sacituzumab govitecan

chemotherapy, +1 more type

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

~31 mi. (Offenbach, Germany, +144 more cities)

GSK Investigational Site

Endometrial Carcinoma

carboplatin, +3 more drugs

chemotherapy, +2 more types

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~35 mi. (Frankfurt am Main, Germany, +140 more cities)

Krankenhaus Nord-West GmbH ( Site 0208)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~35 mi. (Frankfurt am Main, Germany, +199 more cities)

Krankenhaus Nord-West GmbH ( Site 0472)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~35 mi. (Frankfurt am Main, Germany, +131 more cities)

Krankenhaus Nordwest ( Site 1205)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~35 mi. (Frankfurt am Main, Germany, +93 more cities)

Universitaetsklinikum Frankfurt ( Site 1301)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~35 mi. (Frankfurt am Main, Germany, +144 more cities)

Universitatsklinikum Frankfurt

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants

~35 mi. (Frankfurt am Main, Germany, +71 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

cobolimab, +2 more drugs

chemotherapy, +1 more type

Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

~35 mi. (Frankfurt am Main, Germany, +18 more cities)

University Hospital of Frankfurt (Main)

CD19 Expression

B-Cell Acute Lymphoblastic Leukemia

blinatumomab

immunotherapy

De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

~35 mi. (Frankfurt am Main, Germany, +8 more cities)

Prof. Claus Rödel

CDKN2A Overexpression, +2 more biomarkers

Oropharyngeal Squamous Cell Carcinoma

chemotherapy, +1 more drug

chemotherapy, +1 more type

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~41 mi. (Heidelberg, Germany, +172 more cities)

Thoraxklinik-Heidelberg gGmbH

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy